Grifols expands its Blood Typing Solutions portfolio

Grifols has announced they have licensing approval from the FDA to commercialise a range of antisera reagents designed for routine and complex immunohematology testing. Grifols portfolio now includes the following antisera reagents, most of which require no incubation time:
• ABO & Rh monoclonal antisera – An anti-D that detects the DVI variant (IgM/IgG blend), in addition to two other products for anti-D testing
• Rare antisera – A wide range of high-quality monoclonal antisera for typing rare antigens
• Anti-human globulin sera – a wide range of polyspecific and monospecific anti-globulins
Carsten Schroeder, President, Grifols Diagnostic Division, said “Accelerating growth in the U.S. transfusion medicine market is a strategic objective for Grifols. The addition of these reagents to our blood typing solutions portfolio significantly broadens our product offering and delivers increased value to our customers.”